Horsham, Pennsylvania – December 21, 2009: Liquent, Inc. (“Liquent”), a provider of software and service solutions designed to support the regulatory business processes of life sciences companies, announced that it has been acquired by Marlin Equity Partners (“Marlin”) from Thomson Reuters.
Based in Los Angeles, CA, Marlin is a leading private investment firm with over $1 billion of capital under management. Liquent is the provider of Liquent InSight®, a fully integrated and scalable regulatory information management platform. InSight can be leveraged throughout a client organization in support of a life sciences company’s development, registration, and manufacturing processes. Through its Regulatory and Clinical Services consulting services team, Liquent also provides a full range of outsourcing services to support the regulatory submission and registration management activities of a life sciences company.
Liquent’s current General Manager, Rick Riegel, will continue his leadership position as the CEO of the company. “We are very excited to be partnering with such a strong private equity firm,” commented Rick Riegel. “Marlin brings substantial financial resources and expertise in the healthcare IT sector. With their backing and Liquent’s comprehensive software and service solutions, industry leadership, and focus on customer service, we look forward to accelerating our growth and ability to service the evolving and rapidly changing needs of the life sciences industry.”
“Marlin recognizes the life sciences industry’s constant struggle with regulatory change, new product approvals, and cost pressures. Marlin’s backing combined with Liquent’s software and outsourcing capabilities positions us well in helping our customers solve complex regulatory challenges,” stated Jim Brady, Healthcare Operating Partner at Marlin Equity Partners.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.